A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Ovarian Cancer|Colorectal Cancer|Cervical Cancer|Renal Cell Carcinoma
Interventions: DRUG: Durvalumab|DRUG: Tremelimumab
Sponsor: Ludwig Institute for Cancer Research
Collaborators: MedImmune LLC|Cancer Research Institute, New York City